THC Effects on Glucose in Type 2 Diabetes

• Status: Not yet recruiting
• Trial end date: 2026-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the effects THC has on Glucose Metabolism and Endothelial Functioning in participants with Type 2 Diabetes. The participants will complete blood tests and tests to measure energy expenditure, CVD risks, and glucose metabolism. These tests will be performed prior to start of treatment and again after 2-weeks of treatment with the THC or placebo.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Collaborator: Center For Medicinal Cannabis Research at UC San Diego Health

Criteria

Inclusion Criteria:

• Males and Females 21-70 years old at the time of screening.

• Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study.

• Male subjects must be willing to use clinically acceptable method of contraception during the entire study.

• Have a clinical diagnosis of Type 2 Diabetes on a stable medication regimen for at least 3 months.

• BMI > 25 kg/m2).

• HbA1c < 10%).

• Negative urine toxicology result at screening visit.

• Able to provide written informed consent approved by an Institutional Review Board (IRB).

Exclusion Criteria:

• History or presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might put the participant at increased risk of adverse events (e.g., history of psychotic disorder, clinically significant mood and/or anxiety disorder, liver, or renal disease).

• No prior history of myocardial infarction, stroke or heart failure.

• Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion.

• Hemoglobin < 9g/dL.

• Liver enzymes ≥ 2 times upper normal limit and/or clinical signs/symptoms consistent with liver disease, including but not limited to nausea, vomiting, jaundice, itching, abdominal pain, or edema.

• History of clinically significant adverse events associated with cannabis intoxication (e.g., severe anxiety and panic, paranoia and psychosis, sustained tachycardia, or severe hypotension).

• History of seizures, head trauma, or other history of CNS insult that could predispose the participant to seizures.

• Use of any THC containing products within 30 days prior to the screening visit.

• Current use of tobacco products.

• Individuals who are pregnant or lactating/breastfeeding.

• Current use of insulin to treat Type 2 Diabetes.

• Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits.

• Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.